About
Activity
20K followers
-
Nora Zartler shared thisNora Zartler shared thisMannKind Corporation is committed to joining the global effort to overcome the COVID-19 crisis. We have initiated a collaboration with Immix Biopharma, Inc. to prepare a dry powder formulation of a compound with the potential to treat acute respiratory distress syndrome, a complication of COVID-19. The immediate focus of this effort is to rapidly develop prototype powders, which will then be assessed for their potential to be used therapeutically. Our formulation and drug development expertise as well as our excess manufacturing capacity will be deployed as necessary to help protect humankind from this global health crisis. To see full press release, please visit http://bit.ly/2U28QAE
-
Nora Zartler shared thisCheck out this job at MannKind Corporation: https://lnkd.in/ecYp788 #elite
-
Nora Zartler shared this***Exciting opportunity with MannKind Corporation in Austin, TX! Looking for a top performing, science driven, results oriented sales professional to sell Afrezza, the only inhaled insulin. Must have a "hunter" mentality. Exciting time to be a part of a growing company! Competitive compensation, benefits, stock, and great company culture! Please apply on the company website (mannkindcorp.com) and/or direct message me. Prior specialty pharmaceutical or medical sales experience preferred. Nora Zartler District Business Manager Gulf Coast District MannKind Corporation (281) 723-4629 nzartler@mannkindcorp.com http://www.afrezza.com/
-
Nora Zartler shared this***Exciting opportunity with MannKind Corporation in New Orleans! Looking for a top performing, science driven, results oriented sales professional to sell Afrezza, the only inhaled insulin. Must have a "hunter" mentality. Exciting time to be a part of a growing company! Competitive compensation, benefits, stock, and great company culture! Please apply on the company website and/or direct message me. Prior specialty pharmaceutical or medical sales experience preferred. Nora Zartler Regional Business Manager South Central District MannKind Corporation nzartler@mannkindcorp.com http://www.afrezza.com www.mannkindcorp.com
-
Nora Zartler liked thisNora Zartler liked thisMannKind successfully saw its first pre-shipment of Afrezza® (insulin human) Inhalation Powder depart its Danbury, CT-based manufacturing facility headed to India. It was announced by Cipla Ltd. in December 2024 that the Central Drugs Standard Control Organisation (CDSCO) granted approval of Afrezza in adults in India.
-
Nora Zartler liked thisNora Zartler liked thisMannKind is pleased to announce the U.S. FDA has accepted for review its supplemental new drug application (sNDA) seeking approval of FUROSCIX ReadyFlow™ Autoinjector (SCP-111 furosemide injection) for the treatment of edema in adults with chronic heart failure or chronic kidney disease. Click here to read more: https://bit.ly/4ap35V9
-
Nora Zartler liked thisNora Zartler liked thisMannKind is proud to share that “Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease” (NTM) was published ahead of print in the Journal of Aerosol Medicine and Pulmonary Drug Delivery. Underway globally, the ICoN-1 phase 3 clinical trial is designed to evaluate the efficacy and safety of Inhaled Clofazimine (MNKD-101) on top of guideline-based therapy. Read more: https://bit.ly/4gGHt7K
-
Nora Zartler liked thisNora Zartler liked thisOn #WomenPharmacistDay, we celebrate the vital role women pharmacists play in advancing science and expanding access to care. At MannKind, we’re honored to work alongside inspiring women whose expertise and compassion make a difference for patients every day.
-
Nora Zartler liked thisWe are excited to welcome the SC Pharma team to MannKind! Looking forward to building a strong future together!Nora Zartler liked thisMannKind has successfully completed the acquisition of scPharmaceuticals. We’re excited to welcome the scPharmaceuticals team and look forward to working together to transform chronic disease care through innovative, patient-centric solutions in cardiometabolic and orphan lung diseases. 🔗Click here to read more: http://bit.ly/46XgRLp
-
Nora Zartler liked thisNora Zartler liked thisMannKind has successfully completed the acquisition of scPharmaceuticals. We’re excited to welcome the scPharmaceuticals team and look forward to working together to transform chronic disease care through innovative, patient-centric solutions in cardiometabolic and orphan lung diseases. 🔗Click here to read more: http://bit.ly/46XgRLp
-
Nora Zartler liked thisNora Zartler liked thisMannKind is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes. If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy. Click here to read more: https://bit.ly/48xsNUu
Experience & Education
Honors & Awards
-
2014 Pinnacle of Excellence Award
-
-
2019 Circle of Excellence Award
-
-
2020 Circle of Excellence Award
-
-
INNOVEX Manager’s Excellence Award 2004
-
-
MVP Award Voted by GAMMA Managers 2005
-
-
MVP Award Voted by NOVAQUEST Managers 2005
-
-
MVP Award Voted by NovaQuest Managers 2004
-
-
Peer Award Winner 2004 Eli Lilly and Company, Sales Training and Development
-
-
President’s Council 2005
-
-
President’s Council 2006
-
-
Q1 2017–Awarded 1st ALL IN DBM Award
-
-
Q1 2019 DBM of the Quarter
-
-
Q2 2019 DBM of the Quarter
-
-
Q2 2020 DBM of the Quarter
-
-
Q2 2021 DBM of the Quarter
-
-
Q2 2021 District of the Quarter
-
-
Q3 2021 DBM of the Quarter
-
-
Q4 2017 DBM ALL IN Award
-
-
Ryder Cup Award 2006
-
-
Teamwork Award Western Region 2004
-
-
Teamwork Award Western Region 2006
-
Recommendations received
1 person has recommended Nora
Join now to viewOther similar profiles
Explore more posts
-
Hamilton Health Box
Preventive care can change outcomes. And sometimes, it can change a life. Over the past few months, we audited breast cancer screening across our Houston clinics. Of 65 mammograms performed, 9 patients required further testing, and 1 patient was diagnosed with Stage I breast cancer. Because it was identified early, she is now able to move forward with treatment at a stage where the reported 5-year survival rate is 99%. This is why convenient access to preventive care matters. When employees have access to screenings where they work, potential health concerns can be identified earlier, treatment can begin sooner, and employers can help remove barriers that may otherwise delay care. Preventive care is more than a benefit. It is an investment in people. Learn more about how onsite care can support your workforce by visiting our website: www.hamiltonhealthbox.com #PreventiveCare #BreastCancerAwareness #OnsiteHealthcare #EmployeeHealth #HamiltonHealthBox
-
Accelerate Fund
Access to quality breast cancer screening shouldn't depend on where you live or your economic situation. Syantra Inc. has partnered with the Alamo Breast Cancer Foundation to expand early detection and increase access to care for women of all ages and backgrounds—particularly underserved populations who face barriers to traditional screening like mammograms. The partnership brings together ABCF's powerful network of clinicians, scientists, and patient advocates with Syantra's innovative Onco-ID Breast technology. They'll expand clinical studies, work toward insurance reimbursement, and help address screening challenges for women with dense breast tissue. Congrats to CEO Rob Lozuk, Dr. Kristina Rinker and the entire Syantra team on this milestone partnership that will help detect breast cancer earlier and save lives! See the news: https://lnkd.in/gkKT5aKZ #BreastCancer #HealthTech #AlbertaTech
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content